Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

November 22, 2022

Study Completion Date

November 22, 2022

Conditions
COVID-19
Interventions
DRUG

Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly

lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days

DRUG

Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled

lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days

DRUG

Standard of care

The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)

Trial Locations (10)

Unknown

"Budgetary institution of the Chuvash Republic Emergency Hospital", Cheboksary

City clinical Hospital №24, Moscow

Infectious Clinical Hospital No.1, Moscow

State Budgetary Healthcare Institution City Clinical Hospital named after S. I. Spasokukotskiy of Moscow Healthcare Department, Moscow

Regional Clinical Hospital, Ryazan

Ryazan State Medical University named after academician I.P. Pavlov of Ministry of Health of the Russian Federation, Ryazan

Ogarev Mordova State University of Ministry of Health of the Russian Federation, Saransk

City Hospital No. 40 Kurortny District, Sestroretsk

"Regional State Budget Healthcare Institution Clinical hospital No. 1", Smolensk

Voronezh Regional Clinical Hospital No.1, Voronezh

All Listed Sponsors
lead

Promomed, LLC

OTHER